Overview
- The Science Translational Medicine paper reports that twice-daily intranasal CR9114 was safe and well tolerated in 143 healthy adults.
- Nasal samples from participants neutralised multiple influenza A and B strains after dosing in the phase 1 study.
- Because the antibody clears from the nasal surface in about three hours, twice-daily administration maintained effective mucosal levels.
- The same intranasal formulation protected macaques from influenza challenge, mirroring the human-use device and dosing approach.
- Researchers observed nasal antibody concentrations far higher than with intravenous delivery using smaller doses, highlighting the advantage of local administration.